Annual Lung SPORE Workshop (Abstract Submission)
75 submissions
Created | First Name | Last Name | Phone | Select a Session Topic | Abstract Title | First Author First Name | First Author Last Name | Affiliation | List of Additional Authors | Your Abstract Submission | Upload Abstract | Special Characters Included? | Abstract Review Status | Upload Poster | Poster Uploaded | Operations | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mon, 05/13/2024 - 12:50 | Robert | Hsu | robert.hsu@med.usc.edu | 9148153821 | Session 2: Health Disparities in Lung Cancer | Real-World Molecular Testing Disparities at a Large Academic Institution in Los Angeles |
Robert | Hsu | University of Southern California Norris Comprehensive Cancer Center |
|
Abstract_Submission.pdf |
Hsu_USC_Session 2.docx945.73 KB
|
No | ||||
Wed, 04/03/2024 - 17:40 | Cecil | Han | ch1182@georgetown.edu | 2026878634 | Session 1: Oncogene-driven lung cancers and resistance to targeted therapies, Session 6: Cancer Biology | The emerging role of deubiquitinating enzyme USP13 in lung cancer plasticity | Juntae | Kwon | Georgetown University School of Medicine | Abstract_Submission.pdf | No | Approved to be a Speaker | |||||
Sun, 03/31/2024 - 18:56 | Loretta | Erhunmwunsee | lorettae@coh.org | 6262187287 | Session 2: Health Disparities in Lung Cancer | Reducing Racial Residential Segregation Lowers the Risk of Lung Cancer in African Americans | Yi | Xiao | COH |
|
Abstract_Submission.pdf | No | Approved to be a Speaker | ||||
Fri, 03/29/2024 - 13:18 | Victoria | Seewaldt | victoria.seewaldt@me.com | Session 2: Health Disparities in Lung Cancer | The impact of diverse clinical trials personal on the diversity clinical trials participants | Victoria | Seewaldt | City of Hope |
|
Abstract_Submission.pdf |
Introduction.docx19.63 KB
|
No | Approved to be a Poster Presenter | ||||
Mon, 03/25/2024 - 13:09 | Samrat | Kundu | skundu@mdanderson.org | 2039093633 | Session 1: Oncogene-driven lung cancers and resistance to targeted therapies | Identifying resistant mechanisms to direct KRAS-inhibitors | Samrat | Kundu | UT MD Anderson Cancer Center | Abstract_Submission.pdf | No | Approved to be a Speaker | |||||
Mon, 03/18/2024 - 14:34 | Ken | Westover | kenneth.westover@utsouthwestern.edu | Session 1: Oncogene-driven lung cancers and resistance to targeted therapies | The On-Target MRTX1133 Resistance Mutation KRAS(R68S) Acts by Enhancing Lung Adenocarcinoma Cell Fitness | Zhiwei | Zhou | UT Southwestern Medical Center |
|
Abstract_Submission.pdf | No | Approved to be a Speaker | |||||
Thu, 03/14/2024 - 01:26 | Alexandra | Potter | apotter8@mgh.harvard.edu | 2538829777 | Session 2: Health Disparities in Lung Cancer | The Impact of Removing the 15-year Since Quitting Smoking Criterion on Lung Cancer Screening Eligibility | Alexandra | Potter | Massachusetts General Hospital |
|
Abstract_Submission.pdf | No | Approved to be a Speaker | ||||
Wed, 03/13/2024 - 16:10 | Luisa | Solis Soto | lmsolis@mdanderson.org | 8327941469 | Session 3: Immuno-oncology | Comparison of Spatial transcriptomic platforms in lung adenocarcinoma tissue samples | Nejla | Ozirmak | UT-MDACC |
|
Abstract_Submission.pdf |
SolisSoto_MDACC_Session3.docx14.24 KB
|
Yes | Approved to be a Poster Presenter | |||
Wed, 03/13/2024 - 08:39 | Tianxiang | Zhang | tianxiang.zhang@yale.edu | 2032857436 | Session 3: Immuno-oncology | Upregulated PLA2G10 in cancer impairs T-cell infiltration to dampen immunity | Tianxiang | Zhang | Yale University |
|
Abstract_Submission.pdf | No | Approved to be a Speaker | ||||
Mon, 03/11/2024 - 17:58 | Hye Mi | Kim | hyk61@pitt.edu | 4122300387 | Session 3: Immuno-oncology | Development and Induction of Tertiary Lymphoid Structures in Lung Cancer for Improved Immunotherapeutics | Hye Mi | Kim | University of Pittsburgh School of Medicine |
|
Abstract_Submission.pdf | No | Approved to be a Speaker | ||||
Mon, 03/11/2024 - 15:50 | Kristin | Lastwika | klastwik@fredhutch.org | 206-667-5267 | Session 4: Small Cell Lung Cancer | Plasma Autoantibodies Identify Citrullinated Transferrin Receptor Neoepitopes in Small Cell Lung Cancer | Kristin | Lastwika | FHCC |
|
Abstract_Submission.pdf |
Lastwika_FHCC_Session4.docx16.66 KB
|
No | Approved to be a Speaker | |||
Mon, 03/11/2024 - 15:45 | Jessica | Konen | jessica.marie.konen@emory.edu | 4047783558 | Session 3: Immuno-oncology, Session 6: Cancer Biology | Loss of miR-29 as a mechanism of diminished anti-PD-1 response in lung cancer | Jessica | Konen | Department of Hematology and Medical Oncology , Emory University |
|
Abstract_Submission.pdf |
Lung SPORE abstract.docx14.8 KB
|
No | Approved to be a Speaker | |||
Mon, 03/11/2024 - 15:01 | Janet | Freeman-Daily | janet.f-d@comcast.net | 253-606-2173 | Session 1: Oncogene-driven lung cancers and resistance to targeted therapies | Partnering with Patient Research Advocates | Janet | Freeman-Daily | Fred Hutch SPORE (patient advocate) |
|
Abstract_Submission.pdf | No | Approved to be a Speaker | ||||
Mon, 03/11/2024 - 14:56 | Florian | Fintelmann | fintelmann@mgh.harvard.edu | 6178490063 | Session 5: Early Detection and Screening | Significance of image acquisition parameters for Sybil’s ability to predict future lung cancer risk on low-dose chest computed tomography | Judit | Simon | MGH |
|
Abstract_Submission.pdf | No | Approved to be a Speaker | ||||
Mon, 03/11/2024 - 14:55 | Elda | Railey | erailey@researchadvocacy.org | 2146839937 | Session 6: Cancer Biology | Identifying Unique Challenges and Opportunities in Incorporating Patient Advocates into the Lung Cancer SPORE Program | Elda | Railey | UTSWMC/MDACC Lung SPORe and Research Advocacy Network |
|
Abstract_Submission.pdf | No | Approved to be a Speaker | ||||
Mon, 03/11/2024 - 14:54 | Michael | Grant | michael.grant@yale.edu | 2033147088 | Session 1: Oncogene-driven lung cancers and resistance to targeted therapies | Efficacy of afatinib in patients with tumors harboring the uncommon EGFR exon 19 deletion, L747_A750delinsP: a pooled analysis | Michael | Grant | Yale University |
|
Abstract_Submission.pdf |
Grant_Yale_Session1.docx76.61 KB
|
No | Approved to be a Poster Presenter | |||
Mon, 03/11/2024 - 14:46 | Austin | Draycott | austin.draycott@yale.edu | 3475969754 | Session 1: Oncogene-driven lung cancers and resistance to targeted therapies | Dihydrouridine synthase 2 sustains levels of tRNACys to inhibit ferroptosis in lung cancer | Austin | Draycott | Yale University |
|
Abstract_Submission.pdf |
DUS2_Lung_SPORE_Abstract.docx14.37 KB
|
No | Approved to be a Poster Presenter | |||
Mon, 03/11/2024 - 14:39 | Tikvah | Hayes | TKHayes@mednet.ucla.edu | Session 1: Oncogene-driven lung cancers and resistance to targeted therapies | Deep Mutational Scanning of EGFR Reveals Potential Domain-Specific TKI Sensitivities in Lung Cancer | Tikvah | Hayes | UCLA | Abstract_Submission.pdf |
Hayes LS 2024 Abstact.docx13.62 KB
|
No | Approved to be a Poster Presenter | |||||
Mon, 03/11/2024 - 14:27 | Hyunmin | Lee | hyunmin.lee@yale.edu | 7739800378 | Session 1: Oncogene-driven lung cancers and resistance to targeted therapies, Session 6: Cancer Biology | LKB1-SIK axis controls SHMT-mediated antioxidant defense in KRAS-mutant lung cancer | Hyunmin | Lee | Yale University |
|
Abstract_Submission.pdf |
Hyunmin Lee-Abstract.docx15.71 KB
|
No | Approved to be a Poster Presenter | |||
Mon, 03/11/2024 - 14:17 | Yichen | Li | yichen.li@yale.edu | 2674085195 | Session 1: Oncogene-driven lung cancers and resistance to targeted therapies | Elucidate Epigenetic Mechanism underlying Tyrosine Kinase Inhibitors (TKIs) Resistance in Lung Adenocarcinoma (LUAD) | Yichen | Li | Yale University |
|
Abstract_Submission.pdf | No | Approved to be a Poster Presenter |